Pegfilgrastim biosimilars have gained prominence in the pharmaceutical industry as effective alternatives to biologic drugs. Primarily used to reduce the risk of infection in patients undergoing chemotherapy, Pegfilgrastim biosimilars help manage chemotherapy-induced neutropenia by stimulating the production of white blood cells. With the global rise in leukaemia cases, which reached 0.58 million in 2023, the […]
Aphel Online